How to buy DURECT Corporation stock

DURECT Corporation is a drug manufacturers-specialty & generic business based in the US. DURECT Corporation shares (DRRX) are listed on the NASDAQ and all prices are listed in US Dollars. DURECT Corporation employs 81 staff and has a trailing 12-month revenue of around 0.00.

DURECT Corporation share price

Use our graph to track the performance of DRRX stocks over time.

DURECT Corporation shares at a glance

• Key figures

Information last updated 2021-04-30.

52-week range	$1.52 - $2.96
50-day moving average	$1.94
200-day moving average	$2.04
Wall St. target price	$6.67
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-0.15

Buy DURECT Corporation shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy DURECT Corporation stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of DURECT Corporation by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

DURECT Corporation financials

Revenue TTM	$30.1 million
Gross profit TTM	$996,000
Return on assets TTM	-9.75%
Return on equity TTM	-45.53%
Profit margin	-1.93%
Book value	$0.20
Market capitalisation	$429.7 million

TTM: trailing 12 months

Shorting DURECT Corporation shares

There are currently 9.5 million DURECT Corporation shares held short by investors – that's known as DURECT Corporation's "short interest". This figure is 3.7% up from 9.1 million last month.

There are a few different ways that this level of interest in shorting DURECT Corporation shares can be evaluated.

DURECT Corporation's "short interest ratio" (SIR)

DURECT Corporation's "short interest ratio" (SIR) is the quantity of DURECT Corporation shares currently shorted divided by the average quantity of DURECT Corporation shares traded daily (recently around 1.1 million). DURECT Corporation's SIR currently stands at 8.39. In other words for every 100,000 DURECT Corporation shares traded daily on the market, roughly 8390 shares are currently held short.

However DURECT Corporation's short interest can also be evaluated against the total number of DURECT Corporation shares, or, against the total number of tradable DURECT Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case DURECT Corporation's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 DURECT Corporation shares in existence, roughly 40 shares are currently held short) or 0.0472% of the tradable shares (for every 100,000 tradable DURECT Corporation shares, roughly 47 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against DURECT Corporation.

Find out more about how you can short DURECT Corporation stock.

DURECT Corporation share dividends

We're not expecting DURECT Corporation to pay a dividend over the next 12 months.

DURECT Corporation share price volatility

Over the last 12 months, DURECT Corporation's shares have ranged in value from as little as $1.52 up to $2.96. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while DURECT Corporation's is 1.4402. This would suggest that DURECT Corporation's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

DURECT Corporation overview

DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops DUR-928, an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid homeostasis, inflammation, and cell survival, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine up to days of in adults. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd. ; Santen Pharmaceutical Co.

Frequently asked questions

What percentage of DURECT Corporation is owned by insiders or institutions?
Currently 1.432% of DURECT Corporation shares are held by insiders and 49.602% by institutions. How many people work for DURECT Corporation?
Latest data suggests 81 work at DURECT Corporation. When does the fiscal year end for DURECT Corporation?
DURECT Corporation's fiscal year ends in December. Where is DURECT Corporation based?
DURECT Corporation's address is: 10260 Bubb Road, Cupertino, CA, United States, 95014-4166 What is DURECT Corporation's ISIN number?
DURECT Corporation's international securities identification number is: US2666051048 What is DURECT Corporation's CUSIP number?
DURECT Corporation's Committee on Uniform Securities Identification Procedures number is: 266605104